SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced the appointment of Dr. Marco Gottardis as a director and member of the Company's Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, effective July 11, 2024. Dr. Got ...

They don't have the most exciting businesses, but they have a lot to offer nonetheless.Healthcare never sleeps. There is always demand for medical services, regardless of the state of the economy. Companies that offer these necessary goods and are innovative enough to keep up with the changing trends in the sector tend to last. That describes Johnson & Johnson (JNJ 0.12%) and Medtronic (MDT -0.15%) well. Both are among the largest healthcare companies in the world, have proven innovative abilities, and have ...

文章核心观点 - 2024年第二季度财报季已经全面展开,预计标普500指数将再次实现盈利增长[1] - 下周将有多家知名公司如Netflix、台积电和强生公司发布财报,值得关注[2] Netflix - Netflix的订阅者数量指标将是关键,公司将从2025年第一季度开始不再报告季度会员数[4] - 最新一季度Netflix的总订阅用户达到2.696亿,同比增长16%,连续4个季度超出预期[5] - Netflix的盈利能力和营收增长都有所改善,预计本季度每股收益将增长43%,收入增长17%[6] 台积电 - 受益于人工智能热潮,台积电股价今年已涨超80%,大幅跑赢大盘[9] - 本季度每股收益预计增长20%至1.37美元,收入预计增长5%至202亿美元,同比增29%[10] - 投资者对台积电未来增长前景乐观,估值有所扩张,但PEG仍在合理区间[11] - 台积电近期还宣布将派息提高10%,深受重视收益的投资者青睐[12] 强生公司 - 强生公司股价在过去3年中一直横盘整理,下跌4%,但盈利表现一直较为出色[13] - 本季度每股收益预计为2.71美元,较4月中旬的预期下调1%[15][17] - 收入预计同比下降12%至224亿美元[16]

The upcoming report from Johnson & Johnson (JNJ) is expected to reveal quarterly earnings of $2.71 per share, indicating a decline of 3.2% compared to the year-ago period. Analysts forecast revenues of $22.38 billion, representing a decrease of 12.3% year over year.Over the last 30 days, there has been a downward revision of 0.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the co ...

Recession-proof stocks offer investors a safe harbor to shield their portfolios from downside risk.The stock market has cooled off following its AI-powered surge for the last two years. While most experts have called for a soft economic landing, the looming possibility of a recession next year complicates the investing landscape. Hence, the focus is now more on resilient and operationally efficient companies that can hold their own during economic downturns.These businesses boast robust fundamentals thanks ...

文章核心观点 - 约翰逊&约翰逊(JNJ)将于2024年7月17日发布第二季度业绩报告 [2] - 分析师预期JNJ第二季度调整后每股收益为2.69美元,同比下降3.9% [3] - 全年来看,分析师预测JNJ调整后每股收益为10.54美元,同比增长6.3% [3] - JNJ管理层给出的调整后每股收益中值指引为10.65美元,同比增长7.4% [3] - JNJ过去十年调整后每股收益中值比报告每股收益高46% [11] 根据目录分别总结 第二季度业绩预期和历史业绩 - 分析师预期JNJ第二季度调整后每股收益为2.69美元,同比下降3.9% [3] - 过去16年JNJ每季度每股收益惊喜平均仅为0.44% [6] - JNJ过去两年业绩预测准确性很高 [6][7] 对JNJ盈利质量的深入分析 - JNJ过去十年调整后每股收益中值比报告每股收益高46% [11] - 2023年、2022年、2019年和2017年调整幅度最大 [12] - 2023年调整主要来自诉讼费用和无形资产摊销 [13][14] - 2022年、2019年和2017年调整主要也来自这两项 [16][17] - 对新冠疫苗相关成本和重组费用的调整不合理 [15][16] - 总体来看,JNJ的调整不会对估值产生重大影响 [18]

During stock investing, having a list of the top undervalued stocks can offer lucrative opportunities for value growth and portfolio stability. Here are three stocks whose intrinsic value exceeds their current market price, promising potential gains as the market corrects itself. The fundamentals that drive these stocks are operational efficiency, market penetration and innovation. These elements support these companies’ ability to capitalize on the inefficiencies of the restaurant, pharmaceutical and footw ...

In an era where some investors prioritize stable income and reliable returns, artificial intelligence (AI) has identified three standout dividend stocks poised to shine in the latter half of 2024. These companies have built a track record of resilience, consistent performance, and a commitment to rewarding shareholders through reliable dividend distributions.In this line, Finbold turned to OpenAI’s latest and most advanced AI platform, ChatGPT-4o, to gather insights on the must-have dividend stocks for the ...

JHVEPhoto In my last article, I called Johnson & Johnson (NYSE:JNJ) (NEOE:JNJ:CA) a very cautious “Buy” but since my last article Johnson & Johnson continued to decline further and the stock lost about 9% in value during the last 10 months. Especially when comparing the performance to the S&P 500 (SPY) which increased 23% in the same timeframe, we have to see Johnson & Johnson rather as a disappointment. Johnson & Johnson is not really declining steeply, but the stock is slowly creeping lower and has re ...

CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S. FDA for the treatment of patients with multiple myeloma who have had at least one prior line of therapyRARITAN, N.J., July 2, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today positive results from a prespecified second interim analysis of the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) compared to standard therapies of pomalidomide, bortezomib and dexamethasone (P ...